Learn about Research & Clinical Trials

Pirfenidone to Prevent Fibrosis in Ards.

Study Purpose

Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury and a major cause of Intensive Care Unit (ICU) admission worldwide. Despite a large number of randomized clinical trials, a specific and effective pharmacological approach for patients with ARDS is still lacking. Fibroproliferation is a crucial part of the host defence response, and severe fibrotic lung disease affects ARDS patients even years after acute phase resolution. Pirfenidone is an oral anti-fibrotic drug, approved and largely used for treatment of idiopathic pulmonary fibrosis (IPF). The effect of Pirfenidone in ARDS has been evaluated only in animal models. This is a randomized controlled study to evaluate for the first time the efficacy of Pirfenidone in ARDS.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

Concomitant presence of:

- ARDS (moderate and severe) - Berlin definition.

1. Within 1 week of a known clinical insult or new or worsening respiratory symptoms. 2. Bilateral opacities on CXR which are not fully explained by effusions, lobar/lung collapse or nodules. 3. Respiratory failure not fully explained by cardiac failure or fluid overload. 4. PaO2/FiO2<200 mmHg with PEEP<=5 cmH2O (invasive mechanical ventilation)

- Inflammatory ARDS phenotype (28), defined by at least one of the following: 1.

High plasma levels of inflammatory biomarkers. 2. Vasopressor dependence. 3. Lower serum bicarbonate or increased serum lactate.

- Informed consent expressed by the patient or by legal representative or on the Ethical Committee indication.

- Age >=18 years.

Exclusion Criteria:

- Intubated and mechanically ventilated via an endotracheal or tracheostomy tube (>7 days) up to the time of randomization.

- ARDS severe or moderate for more than 36 hours.

- Untreated pulmonary embolism, pleural effusion or pneumothorax as the primary cause of ARF.

- ARF fully explained by left ventricular failure or fluid overload.

- Consent declined.

- Severe chronic respiratory disease requiring domiciliary ventilation.

- Clinical suspicion for significant restrictive lung disease.

- Pregnant women or women of childbearing potential who are sexually active.

- Known allergy to pirfenidone.

- Concomitant use of fluvoxamine.

- Known severe hepatic failure.

- Known severe renal failure or necessity of dialysis not related to acute disease.

- Little chance of survival (SAPS II score>75)

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT05075161
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	Phase 3
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Università Vita-Salute San Raffaele
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Giovanni Landoni, Professor
Principal Investigator Affiliation	Vita-Salute San Raffaele University
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	Italy
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Acute Respiratory Distress Syndrome (ARDS)

Additional Details

Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung injury, associated with increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. ARDS represents 10.4% of total ICU admissions and 23.4% of all patients requiring mechanical ventilation and the hospital mortality rate remains as high as 40%. Optimal care for patients with ARDS includes PEEP, muscle relaxation, protective ventilation, prone position, conservative fluid strategy. Pharmacological interventions focused on dampening the pro-inflammatory response in the initial phase of ARDS, on reduction of pulmonary oedema and on improvement of repair mechanisms. Besides treatment with glucocorticosteroids, none of the other pharmacological interventions tested so far in clinical trials showed a significant reduction in morbidity and mortality. Many ARDS patients survive the acute inflammation phase but develop remarkable pulmonary fibrosis. In hospital mortality is significantly lower (24%) than 1-y mortality after hospital discharge (41%) regardless of the etiology of ARDS. Although a protective ventilation strategy can improve short-term survival in ARDS subjects, there is no difference in pulmonary function compared with standard ventilation treatment up to 2 years after the acute-phase resolution. Pulmonary fibrosis was observed in 53% of ventilated patients who had ARDS for five days and their mortality rate was 57% compared with 0% in patients without pulmonary fibrosis. The purpose of this study is to provide a large multicenter RCT with an adequate size to explore the efficacy of Pirfenidone in ARDS patients.

Arms & Interventions

Arms

Experimental: Pirfenidone

Patients randomized to Pirfernidone Group will receive tables of 267 mg

Placebo Comparator: Placebo

Patients randomized to Placebo Group will receive 5 ml of Water

Interventions

Drug: - Pirfenidone

From days 1-7: 801mg/day; from days 8-14:1602mg/day, from day 15 to ICU discharge 2403 mg/day. All drugs will be delivered by a nasogastric tube divided in 3 daily doses.

Drug: - Placebo

All drugs will be delivered by a nasogastric tube divided in 3 daily doses.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.